WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Protalix Biotherapeutics earnings were $2.9M for the trailing 12 months ending Dec 31, 2024, with -66.7% growth year over year. The latest PLX earnings report on Dec 31, 2024 announced Q4 2024 earnings of $6.5M, up 100.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PLX reported annual earnings of $2.9M, with -64.7% growth. The next PLX earnings date is May 8, 2025.

PLX past earnings growth

How has PLX's earnings growth performed historically?

Company
-66.67%
Industry
12.22%
Market
64.82%
PLX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PLX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

PLX earnings history

Current Revenue
$53.4M
Current Earnings
$2.9M
Current Profit Margin
5.5%

PLX Return on Equity

Current Company
8.8%
Current Industry
-1.4%
Current Market
34.2%
PLX's Return on Equity (8.8%)... subscribe to Premium to read more.
High Return on Equity Performance

PLX undefined

Current Company
3.7%
Current Industry
0.2%
PLX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PLX announces earnings.

PLX undefined

Current Company
10.91%
Current Industry
6.6%
PLX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PLX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PLX$6.52M$2.93M-66.67%$0.04
RAPT-$126.33M-$129.87MN/A-$3.19
SGMO-$88.75M-$97.94MN/A-$0.49
CKPT-$46.47M-$46.47MN/A-$1.84
CTNM-$41.13M-$42.26MN/A-$2.18
View Top Biotech Stocks

PLX earnings dates

Next earnings date
May 8, 2025

Protalix Biotherapeutics Earnings Reports & History FAQ

What were Protalix Biotherapeutics's earnings last quarter?

On PLX's earnings call on Invalid Date, Protalix Biotherapeutics (NYSEMKT: PLX) reported Q4 2024 earnings per share (EPS) of $0.09, up 190% year over year. Total PLX earnings for the quarter were $6.49 million. In the same quarter last year, Protalix Biotherapeutics's earnings per share (EPS) was -$0.10.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.

When does Protalix Biotherapeutics report earnings?

The next PLX earnings date is Invalid Date. Add PLX to your watchlist to be reminded of Protalix Biotherapeutics's next earnings date.

Is Protalix Biotherapeutics profitable or losing money?

As of the last Protalix Biotherapeutics earnings report, Protalix Biotherapeutics is currently profitable. Protalix Biotherapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $2.93 million, a 64.73% decrease year over year.

What was PLX's earnings growth in the past year?

As of Protalix Biotherapeutics's earnings date in Invalid Date, Protalix Biotherapeutics's earnings has grown -66.67% year over year. This is 78.89 percentage points lower than the US Biotechnology industry earnings growth rate of 12.22%. PLX earnings in the past year totalled $2.93 million.

What are Protalix Biotherapeutics's earnings expectations?

The current EPS estimate for Protalix Biotherapeutics's earnings report in Invalid Date is -$0.02.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.